Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 65.75 Billion KRW | 3.6% |
| 2022 | 63.46 Billion KRW | 30.63% |
| 2021 | 48.58 Billion KRW | 14.34% |
| 2020 | 42.49 Billion KRW | 1.41% |
| 2019 | 41.9 Billion KRW | 3.4% |
| 2018 | 40.52 Billion KRW | 2.34% |
| 2017 | 39.59 Billion KRW | 5.32% |
| 2016 | 37.59 Billion KRW | 5.18% |
| 2015 | 35.74 Billion KRW | -16.07% |
| 2014 | 42.59 Billion KRW | 11.75% |
| 2013 | 38.11 Billion KRW | -3.11% |
| 2012 | 39.33 Billion KRW | -16.12% |
| 2011 | 46.89 Billion KRW | 9.48% |
| 2010 | 42.83 Billion KRW | -12.38% |
| 2009 | 48.89 Billion KRW | 0.76% |
| 2008 | 48.52 Billion KRW | 27.97% |
| 2007 | 37.91 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 19.53 Billion KRW | 12.44% |
| 2024 Q1 | 17.23 Billion KRW | -0.64% |
| 2023 FY | 65.75 Billion KRW | 3.6% |
| 2023 Q4 | 17.34 Billion KRW | 202.11% |
| 2023 Q2 | 16.91 Billion KRW | 6.3% |
| 2023 Q1 | 15.9 Billion KRW | -7.37% |
| 2023 Q3 | -16.98 Billion KRW | -200.42% |
| 2022 Q4 | 17.17 Billion KRW | 5.86% |
| 2022 FY | 63.46 Billion KRW | 30.63% |
| 2022 Q2 | 15.18 Billion KRW | 2.0% |
| 2022 Q3 | 16.22 Billion KRW | 6.85% |
| 2022 Q1 | 14.88 Billion KRW | 9.44% |
| 2021 Q2 | 12.2 Billion KRW | 14.58% |
| 2021 Q3 | 12.13 Billion KRW | -0.55% |
| 2021 Q1 | 10.64 Billion KRW | -4.51% |
| 2021 FY | 48.58 Billion KRW | 14.34% |
| 2021 Q4 | 13.6 Billion KRW | 12.09% |
| 2020 Q3 | 11.2 Billion KRW | 12.35% |
| 2020 FY | 42.49 Billion KRW | 1.41% |
| 2020 Q1 | 10.15 Billion KRW | 2.45% |
| 2020 Q2 | 9.97 Billion KRW | -1.74% |
| 2020 Q4 | 11.15 Billion KRW | -0.51% |
| 2019 Q3 | 11.29 Billion KRW | 5.57% |
| 2019 Q4 | 9.91 Billion KRW | -12.28% |
| 2019 Q2 | 10.7 Billion KRW | 7.16% |
| 2019 Q1 | 9.98 Billion KRW | -1.02% |
| 2019 FY | 41.9 Billion KRW | 3.4% |
| 2018 Q3 | 10.46 Billion KRW | -2.69% |
| 2018 FY | 40.52 Billion KRW | 2.34% |
| 2018 Q4 | 10.09 Billion KRW | -3.58% |
| 2018 Q2 | 10.75 Billion KRW | 16.75% |
| 2018 Q1 | 9.21 Billion KRW | -6.08% |
| 2017 FY | 39.59 Billion KRW | 5.32% |
| 2017 Q3 | 10.02 Billion KRW | 0.15% |
| 2017 Q4 | 9.8 Billion KRW | -2.16% |
| 2017 Q2 | 10 Billion KRW | 2.57% |
| 2017 Q1 | 9.75 Billion KRW | 8.78% |
| 2016 Q1 | 9.3 Billion KRW | 7.5% |
| 2016 Q4 | 8.96 Billion KRW | -1.56% |
| 2016 FY | 37.59 Billion KRW | 5.18% |
| 2016 Q3 | 9.11 Billion KRW | -10.73% |
| 2016 Q2 | 10.2 Billion KRW | 9.64% |
| 2015 Q1 | 9.47 Billion KRW | -7.62% |
| 2015 Q4 | 8.65 Billion KRW | -1.63% |
| 2015 Q3 | 8.8 Billion KRW | -0.05% |
| 2015 Q2 | 8.8 Billion KRW | -7.05% |
| 2015 FY | 35.74 Billion KRW | -16.07% |
| 2014 Q3 | 10.76 Billion KRW | -9.09% |
| 2014 Q4 | 10.25 Billion KRW | -4.67% |
| 2014 FY | 42.59 Billion KRW | 11.75% |
| 2014 Q1 | 9.73 Billion KRW | 0.37% |
| 2014 Q2 | 11.83 Billion KRW | 21.59% |
| 2013 Q4 | 9.69 Billion KRW | 7.79% |
| 2013 Q1 | 9.61 Billion KRW | 3.63% |
| 2013 Q2 | 9.79 Billion KRW | 1.93% |
| 2013 FY | 38.11 Billion KRW | -3.11% |
| 2013 Q3 | 8.99 Billion KRW | -8.17% |
| 2012 Q3 | 9.8 Billion KRW | -9.76% |
| 2012 Q4 | 9.27 Billion KRW | -5.36% |
| 2012 FY | 39.33 Billion KRW | -16.12% |
| 2012 Q1 | 8.75 Billion KRW | 0.0% |
| 2012 Q2 | 10.86 Billion KRW | 24.11% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 46.89 Billion KRW | 9.48% |
| 2011 Q3 | 10.06 Billion KRW | -13.79% |
| 2011 Q2 | 11.67 Billion KRW | 3.85% |
| 2011 Q1 | 11.23 Billion KRW | 16.07% |
| 2010 FY | 42.83 Billion KRW | -12.38% |
| 2010 Q3 | 11.39 Billion KRW | -2.92% |
| 2010 Q4 | 9.68 Billion KRW | -15.06% |
| 2010 Q2 | 11.74 Billion KRW | 17.21% |
| 2010 Q1 | 10.01 Billion KRW | -14.6% |
| 2009 Q4 | 11.72 Billion KRW | -7.67% |
| 2009 Q1 | 11.28 Billion KRW | -15.66% |
| 2009 Q3 | 12.7 Billion KRW | -3.57% |
| 2009 Q2 | 13.17 Billion KRW | 16.75% |
| 2009 FY | 48.89 Billion KRW | 0.76% |
| 2008 Q1 | 10.97 Billion KRW | 1.39% |
| 2008 Q3 | 11.08 Billion KRW | -15.27% |
| 2008 FY | 48.52 Billion KRW | 27.97% |
| 2008 Q2 | 13.08 Billion KRW | 19.25% |
| 2008 Q4 | 13.37 Billion KRW | 20.68% |
| 2007 Q1 | 8.44 Billion KRW | 0.0% |
| 2007 Q2 | 8.99 Billion KRW | 6.48% |
| 2007 Q3 | 9.65 Billion KRW | 7.42% |
| 2007 FY | 37.91 Billion KRW | 0.0% |
| 2007 Q4 | 10.82 Billion KRW | 12.04% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -39.145% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 77.935% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 76.386% |
| HANDOK Inc. | 153.76 Billion KRW | 57.24% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 5.002% |
| Yuhan Corporation | 489.94 Billion KRW | 86.58% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 78.58% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -57.34% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 89.238% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 8.657% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 62.244% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -64.161% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 29.716% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 42.688% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -39.145% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -54.812% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 12.389% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -12.119% |
| JW Holdings Corporation | 301.25 Billion KRW | 78.174% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 74.804% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 83.91% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 72.479% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 48.499% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 3.747% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 62.412% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -39.145% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 73.607% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 88.268% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 72.479% |
| Yuhan Corporation | 489.94 Billion KRW | 86.58% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 66.049% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 5.351% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -17.346% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 72.479% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 47.979% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 44.379% |
| CKD Bio Corp. | 25.19 Billion KRW | -160.962% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 70.382% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 60.178% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 1.003% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 48.499% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 81.252% |
| Boryung Corporation | 285.16 Billion KRW | 76.942% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 24.892% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 62.244% |
| JW Lifescience Corporation | 20.26 Billion KRW | -224.513% |